Acutus Medical

102 articles about Acutus Medical

• Acutus Medical to Showcase Innovative Cardiac Mapping and Ablation Technologies at HRS 2023

  5/15/2023

  Acutus Medical, Inc. is pleased to announce its participation in the upcoming Heart Rhythm Society (HRS) Annual Scientific Sessions in New Orleans, LA from May 19-21, 2023.

• Acutus Medical Reports First Quarter 2023 Financial Results

  5/11/2023

  Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023.

• Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2023

  5/2/2023

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on May 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 8 individuals hired by Acutus in April 2023.

• Acutus Medical to Announce First Quarter 2023 Financial Results

  4/28/2023

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023.

• RECOVER AF Study Reports 91% of First Redo Patients Achieved Freedom from AF at One Year After AcQMap-guided Ablation Therapy

  4/20/2023

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced results from the RECOVER AF study.

• Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results

  4/20/2023

  Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to the release of the RECOVER AF study data (published online in EP Europace)1.

• Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2023

  4/3/2023

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on April 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 7 individuals hired by Acutus in March 2023.

• Acutus Medical Reports Fourth Quarter and Full Year 2022 Financial Results

  3/16/2023

  Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2022.

• Acutus Medical to Announce Fourth Quarter and Full Year 2022 Financial Results

  3/9/2023

  Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023.

• Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2023

  3/1/2023

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on March 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in February 2023.

• Late-Breaking ACQFORCE FLUTTER Trial Meets Primary Endpoint for Safety and Efficacy with the First Gold-Tipped Contact Force Sensing Ablation Catheter

  2/6/2023

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced results from the AcQForce Flutter Study “AcQForce Flutter: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter”.

• Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2023

  2/1/2023

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on February 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 7 individuals hired by Acutus in January 2023.

• Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer

  1/9/2023

  Acutus Medical, Inc. today announced preliminary unaudited results for the fourth quarter and full year 2022.

• Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2023

  1/3/2023

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on January 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 2 individuals hired by Acutus in December 2022.

• Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF Symposium

  12/29/2022

  Acutus Medical, Inc. announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” for presentation during the Late-Breaking Clinical Trials and First Report Investigations session at the AF Symposium in Boston.

• Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic

  12/21/2022

  Acutus Medical, Inc. today announced that the Company has achieved the second milestone under the asset purchase agreement with Medtronic of its left-heart access portfolio with the submission for CE Mark of this portfolio under European Union (EU) Medical Device Regulations (MDR).

• Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping CatheterThe flagship 3D mapping catheter from Acutus Medical has been certified under the new European Medical Device Regulations

  12/6/2022

  Acutus Medical, Inc. today announced receipt of a CE Mark issued under the European Union (EU) Medical Device Regulations (MDR) for its AcQMap 3D Imaging and Mapping Catheter, the world’s only integrated high-resolution ultrasound imaging and non-contact mapping catheter.

• Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2022

  12/1/2022

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on December 1, 2022 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in November 2022.

• Acutus Medical Reports Third Quarter 2022 Financial Results

  11/10/2022

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported results for the third quarter of 2022.

• Acutus Medical Achieves OEM Qualification Milestone in Sale of Left-Heart Access Portfolio to Medtronic

  11/3/2022

  Acutus Medical, Inc. announced that the Company has achieved the first milestone under the asset purchase agreement of its left-heart access portfolio with Medtronic.